Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression

The GBG 26 — TBP study of the German Breast Group addressed the question of whether the treatment of women with HER2-positive metastatic breast cancer with trastuzumab is effective beyond progression (Trastuzumab Beyond Progression TBP). In this study, women with metastatic HER2-positive breast cancer who had progressed on prior trastuzumab treatment were treated either with a combination of trastuzumab (Herceptin(r), Roche Pharma AG, Grenzach-Whylen, Germany) and capecitabine (Xeloda(r), Roche Pharma AG) or capecitabine alone.